Cover Image
市場調查報告書

多發性骨髓瘤:日本的醫藥品的預測與市場分析

Multiple Myeloma - Japan Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 368835
出版日期 內容資訊 英文 162 Pages
訂單完成後即時交付
價格
Back to Top
多發性骨髓瘤:日本的醫藥品的預測與市場分析 Multiple Myeloma - Japan Drug Forecast and Market Analysis to 2023
出版日期: 2015年11月01日 內容資訊: 英文 162 Pages
簡介

本報告提供日本多發性骨髓瘤的治療藥市場相關調查分析,提供您疾病概要和治療指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素·阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
  • 分期
  • 與應答復發標準
  • 症狀
  • 預後
  • QOL

第4章 疾病的管理

  • 治療概要
  • 診斷
  • 臨床診療
  • 日本

第5章 競爭評估

  • 概要
  • 產品簡介:蛋白酶體抑制劑
  • 產品簡介:免疫刺激劑
  • 其他藥效分類

第6章 未滿足需求和機會

  • 概要
  • 高風險患者的治療
  • 和緩性骨髓瘤患者的治療
  • 髓外疾病的治療

第7章 開發平台評估

  • 概要
  • 臨床開發中的有前途藥物
  • 臨床正在開發 (初期)的有前途藥物

第8章 市場預測

  • 日本
    • 預測
    • 主要的活動
    • 推動因素
    • 障礙

第9章 附錄

圖表

目錄
Product Code: GDHC305CFR

The Multiple Myeloma (MM) market is currently dominated by Velcade and Revlimid, and the market is set to undergo substantial growth between 2013 and 2023. The main drivers of growth will be the launch of monoclonal antibodies (mAbs) Empliciti and daratumumab, which will not only provide a new treatment option for MM patients, but will also lengthen the time between relapses, meaning that the duration of Revlimid and/or Velcade treatments will also be longer. Furthermore, the relatively mild safety profile of these mAbs and the significant efficacies demonstrated by these agents will mean that more MM patients will ultimately receive drug treatment. Label extensions of these mAbs, as well as of second-generation proteasome inhibitors ixazomib and Kyprolis, will further increase treatment options for these patients. The biggest constrainers of the MM market are the increasing cost-consciousness of healthcare providers, as the launch and subsequent label extensions of these pipeline agents will lead to a significant expense, which may impact uptake of these drugs. The patent expiries of Revlimid and Velcade will somewhat alleviate healthcare spending on multiple myeloma patients, which may assist in the uptake of mAbs and second-generation PIs in the multiple myeloma market.

Japan will experience significant market growth, driven by the uptake of the latest premium-priced therapies. KOLs identified the reimbursement of drugs in Japan as a significant barrier to market growth, although oncology drugs are generally reimbursed if they demonstrate clinically significant efficacy.

Scope

  • Overview of Multiple Myeloma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2014-2024.
  • Analysis of the impact of key events as well the drivers and restraints affecting Japan Multiple Myeloma market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Multiple Myeloma.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2014-2024 in Japan.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Staging Systems
  • 3.3. Response and Relapse Criteria
  • 3.4. Symptoms
  • 3.5. Prognosis
  • 3.6. Quality of Life

4. Disease Management

  • 4.1. Treatment Overview
  • 4.2. Diagnosis
  • 4.3. Clinical Practice
    • 4.3.1. Primary Therapy for SCT-Eligible Patients
    • 4.3.2. Primary Therapy for Non-SCT Patients
    • 4.3.3. Salvage/Relapse Therapy
    • 4.3.4. Leading Prescribed Drugs
  • 4.4. Japan
    • 4.4.1. Diagnosis
    • 4.4.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles. Proteasome Inhibitors
    • 5.2.1. Velcade (Bortezomib)
    • 5.2.2. Kyprolis (Carfilzomib)
  • 5.3. Product Profiles. Immunomodulators
    • 5.3.1. Revlimid (Lenalidomide)
    • 5.3.2. Pomalyst/Imnovid (Pomalidomide)
  • 5.4. Other Therapeutic Classes

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Treatment of High-Risk Patients
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Treatment of Patients with Smoldering Myeloma
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Treatment of Extramedullary Disease
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Farydak (Panobinostat)
    • 7.2.2. Ixazomib
    • 7.2.3. Empliciti (Elotuzumab)
    • 7.2.4. Daratumumab
    • 7.2.5. Aplidin (Plitidepsin)
  • 7.3. Promising Drugs in Early-Stage Development
    • 7.3.1. Oprozomib (ONX-0912)
    • 7.3.2. Filanesib
    • 7.3.3. SAR650984
    • 7.3.4. Marizomib
    • 7.3.5. Evofosfamide
    • 7.3.6. LGH447
    • 7.3.7. Selinexor (KPT-330)

8. Market Outlook

  • 8.1. Japan
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers. Japan
    • 8.1.4. Barriers. Japan

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Multiple Myeloma Patients
    • 9.4.2. Percent of Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Pricing of Pipeline Agents
    • 9.4.8. Generic Erosion
  • 9.5. Primary Research. KOLs Interviewed for this Report
  • 9.6. Primary Research. High-Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Director
    • 9.7.3. Epidemiologist
    • 9.7.4. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Definition of the Classes of Myeloma
  • Table 2: Staging Systems for Multiple Myeloma
  • Table 3: IMWG Uniform Response Criteria for Multiple Myeloma: Response
  • Table 4: IMWG Uniform Response Criteria for Multiple Myeloma: Progression
  • Table 5: Symptoms of Multiple Myeloma
  • Table 6: Median Survival for Each Stage at Diagnosis of Multiple Myeloma
  • Table 7: Potential Diagnostic Markers that Predict Two-Year Disease Progression
  • Table 8: Summary of Prevalence and Clinical Outcomes of Translocations in Multiple Myeloma
  • Table 9: Treatment Guidelines for Multiple Myeloma
  • Table 10: Definition of the Classes of Myeloma
  • Table 11: Most Prescribed Drugs for Multiple Myeloma by Class in the Global Markets, 2014
  • Table 12: Most-Prescribed Drugs for Multiple Myeloma by Segment in the Global Markets, 2013
  • Table 13: Country Profile - Japan
  • Table 14: Product Profile - Velcade
  • Table 15: Results from the Pivotal Phase III APEX Trial for Velcade
  • Table 16: Results from the Pivotal Phase III VISTA Trial for Velcade
  • Table 17 Results from the Subcutaneous versus Intravenous Velcade Phase III trial
  • Table 18: Common Grade 3 and 4 Adverse Events from Velcade Pivotal Clinical Trials
  • Table 19: Velcade SWOT Analysis, 2015
  • Table 20: Global Sales Forecast ($m) for Velcade, 2013-2023
  • Table 21: Product Profile - Kyprolis
  • Table 22 Summary of Phase III Pivotal Trial Results for Kyprolis
  • Table 23: Summary of Phase II Clinical Trial Efficacy Data for Kyprolis
  • Table 24 Summary of Adverse Events from Key Phase III Pivotal Trials for Kyprolis
  • Table 25: Kyprolis SWOT Analysis, 2015
  • Table 26: Global Sales Forecasts ($m) for Kyprolis, 2013-2023
  • Table 27: Product Profile - Revlimid
  • Table 28 Summary of Phase III Pivotal Trial Results for Revlimid in NDMM Patients
  • Table 29 Summary of Phase III Pivotal Trial Results for Revlimid in RRMM Patients
  • Table 30: Summary of Frequent Grade 3 and 4 AEs in a Phase III Trial for Revlimid
  • Table 31: Revlimid SWOT Analysis, 2015
  • Table 32: Global Sales Forecast ($m) for Revlimid, 2013-2023
  • Table 33: Product Profile - Pomalyst
  • Table 34: Summary of PFS, OS, and ORR from Phase II Trial Data for Pomalyst
  • Table 35: Summary of Phase III Trial Data for Pomalyst
  • Table 36: Pomalyst SWOT Analysis, 2015
  • Table 37: Global Sales Forecasts ($m) for Pomalyst, 2013-2023
  • Table 38: Summary of Other Therapeutic Classes, 2015
  • Table 39: Pipeline Product Profile - Farydak
  • Table 40: Summary of the Phase III PANORAMA 1 Trial of Farydak
  • Table 41: Summary of the Phase III PANORAMA 1 Trial of Farydak in Patients Who Recived at Least Two Prior Lines of Therapy (Including Velcade and an IMiD)
  • Table 42: Summary of the Phase II PANORAMA 2 Trial of Farydak
  • Table 43: Grade 3-4 Adverse Events in the Phase III PANORAMA 1 Trial of Farydak
  • Table 44: Farydak SWOT Analysis, 2015
  • Table 45: Global Sales Forecast ($m) for Farydak, 2013-2023
  • Table 46: Pipeline Product Profile - Ixazomib
  • Table 47: Response Results from the Phase II Study of Ixazomib
  • Table 48: Ixazomib SWOT Analysis, 2015
  • Table 49: Global Sales Forecast ($m) for Ixazomib, 2013-2023
  • Table 50: Pipeline Product Profile - Empliciti
  • Table 51: Summary of the Phase III ELOQUENT 2 trial of Empliciti
  • Table 52: Efficacy Results from the Phase II Study of Empliciti with Velcade and Dexamethasone
  • Table 53: Empliciti SWOT Analysis, 2015
  • Table 54: Global Sales Forecast ($m) for Empliciti, 2013-2023
  • Table 55: Pipeline Product Profile - Daratumumab
  • Table 56: Response Results from the Phase II Study of Daratumumab
  • Table 57: Daratumumab SWOT Analysis, 2015
  • Table 58: Global Sales Forecast ($m) for Ddaratumumab, 2013-2023
  • Table 59: Pipeline Product Profile - Aplidin
  • Table 60: Summary of Phase II Clinical Trial Results for Aplidin
  • Table 61: Summary of Grade 3 and 4 Adverse Events of Aplidin
  • Table 62: Aplidin SWOT Analysis, 2015
  • Table 63: Global Sales Forecast ($m) for Aplidin, 2013-2023
  • Table 64: Summary of Efficacy Data from the Phase Ib/II Clinical Trial of Oprozomib
  • Table 65: Summary of the Phase I Efficacy Results of SAR650984
  • Table 66: Summary of the Phase I Efficacy Results of Evofosfamide
  • Table 67: Japan Sales Forecasts, Multiple Myeloma, 2013-2023 ($m)
  • Table 68: Key Events Impacting Sales for Multiple Myeloma in Japan, 2013-2023
  • Table 69: Japanese Multiple Myeloma - Drivers, 2013-2023
  • Table 70: Japanese Multiple Myeloma - Barriers, 2013-2023
  • Table 71: Multiple Myeloma Diagnosed Incidence, 2013-2023
  • Table 72: Multiple Myeloma Drugs and Pipeline agents, Launch Dates
  • Table 73: Multiple Myeloma Drugs and Pipeline agents, Anticipated Patent Expiries
  • Table 74: Average Cost of Therapy for Velcade
  • Table 75: Average Duration of Treatment (Weeks) for Velcade
  • Table 76: Average Cost of Therapy for Kyprolis ($)
  • Table 77: Average Duration of Treatment (Weeks) for Kyprolis
  • Table 78: Average Cost of Therapy for Revlimid ($)
  • Table 79: Average Duration of Treatment (Weeks) for Revlimid
  • Table 80: Average Cost of Therapy for Pomalyst/Imnovid ($)
  • Table 81 Average Duration of Treatment (Weeks) for Pomalyst/Imnovid
  • Table 82: Average Cost of Therapy for Farydak ($)
  • Table 83: Duration of Treatment (Weeks) for Farydak
  • Table 84: Average Cost of Therapy for Ixazomib ($)
  • Table 85: Duration of Treatment (Weeks) for Ixazomib
  • Table 86: Average Cost of Therapy for Empliciti ($)
  • Table 87: Duration of Treatment (Weeks) for Empliciti
  • Table 88: Average Cost of Therapy for Daratumumab ($)
  • Table 89: Duration of Treatment (Weeks) for Daratumumab
  • Table 90: Average Cost of Therapy for Daratumumab ($)
  • Table 91: Duration of Treatment (Weeks) for Daratumumab
  • Table 92: Numbers of Prescribers Surveyed in Each Country

List of Figures

  • Figure 1: SCT-Eligible Typical Patient Journey
  • Figure 2: Non-SCT-Eligible Typical Patient Journey
  • Figure 3: Velcade's Phase III Development in Multiple Myeloma
  • Figure 4: Kyprolis's Phase III Development in Multiple Myeloma
  • Figure 5: Revlimid's Phase III Development in Multiple Myeloma
  • Figure 6: Pomalyst/Imnovid's Phase III Development in Multiple Myeloma
  • Figure 7: Farydak's Development in Multiple Myeloma
  • Figure 8: Dosing Schedule for Farydak
  • Figure 9: Ixazomib's Development in Multiple Myeloma
  • Figure 10: Empliciti's Development in Multiple Myeloma
  • Figure 11: Daratumumab's Development in Multiple Myeloma
  • Figure 12: Annual Japanese Sales for Multiple Myeloma by Drug, 2013-2023
  • Figure 13: Japanese Sales for Multiple Myeloma by Drug, 2013 and 2023
Back to Top